Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 8.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 221,046 shares of the biotechnology company’s stock after acquiring an additional 16,936 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Rocket Pharmaceuticals were worth $4,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its stake in Rocket Pharmaceuticals by 174.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company’s stock valued at $70,170,000 after acquiring an additional 1,656,111 shares during the period. Vanguard Group Inc. grew its position in Rocket Pharmaceuticals by 18.3% during the 4th quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company’s stock worth $163,264,000 after purchasing an additional 843,552 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Rocket Pharmaceuticals by 11.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,943,160 shares of the biotechnology company’s stock valued at $79,290,000 after buying an additional 314,086 shares during the last quarter. First Turn Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 123.6% in the 2nd quarter. First Turn Management LLC now owns 560,989 shares of the biotechnology company’s stock valued at $12,078,000 after buying an additional 310,119 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Rocket Pharmaceuticals by 75.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,832 shares of the biotechnology company’s stock worth $8,131,000 after buying an additional 129,358 shares during the last quarter. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Wall Street Analyst Weigh In

RCKT has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Chardan Capital reissued a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, September 17th. JPMorgan Chase & Co. increased their target price on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Finally, Scotiabank initiated coverage on Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.75.

Rocket Pharmaceuticals Stock Down 2.1 %

NASDAQ RCKT opened at $17.22 on Friday. The business has a fifty day moving average price of $18.45 and a 200 day moving average price of $20.98. The company has a market cap of $1.56 billion, a P/E ratio of -6.00 and a beta of 1.09. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.79 and a current ratio of 7.79. Rocket Pharmaceuticals, Inc. has a one year low of $15.98 and a one year high of $32.53.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.02). During the same quarter in the prior year, the firm earned ($0.82) EPS. Research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.97 EPS for the current fiscal year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.